CAMP4 Therapeutics (CAMP) said Tuesday data from single ascending dose portion of an early-stage study of CMP-CPS-001 for the treatment of urea cycle disorders showed "favorable" safety results.
"We are pleased to report the safety data from the SAD portion of our Phase 1 study of CMP-CPS-001 for UCDs, showing that the drug has been well-tolerated," said Chief Medical Officer Yuri Maricich.
"We expect 2025 to be a pivotal year as we anticipate reporting MAD safety and key biomarker data in the second half of 2025," Maricich said. MAD refers to multiple ascending dose.
"Results from these studies could enable us to advance the CMP-CPS-001 program into a registrational Phase 2/3 trial in 2026."
Shares of the company were advancing over 4% in after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.